Suppr超能文献

新西兰儿童哮喘吸入性糖皮质激素的使用趋势

Trends in the use of inhaled corticosteroids for childhood asthma in New Zealand.

作者信息

Johansson Maria, Hall Jason, Reith David, Jackson Pam, Tilyard Murray

机构信息

University of Uppsala, Sweden.

出版信息

Eur J Clin Pharmacol. 2003 Sep;59(5-6):483-7. doi: 10.1007/s00228-003-0659-2. Epub 2003 Aug 23.

Abstract

OBJECTIVE

To compare the dispensed volumes and prescribed doses for inhaled corticosteroids (ICS) for children in New Zealand.

DESIGN

Longitudinal analysis of prescribing trends using the Royal New Zealand College of General Practitioners Research Unit database and the Pharm Warehouse database of the New Zealand Health Information System.

SETTING

New Zealand from 1993 to 2001.

SUBJECTS

Children aged 0-5 years and 6-17 years.

MAIN OUTCOME MEASURES

The ratio of potency-adjusted mean daily dose of fluticasone propionate (FP) to beclomethasone (BDP) and dispensed volumes of FP, BDP and budesonide.

RESULTS

The ratio of potency-adjusted mean daily dose of FP to BDP prescribed to children aged 0-17 years ranged from 1.22 to 1.91. With the introduction of FP, the total amount of ICS dispensed to children aged 0-5 years in New Zealand nearly doubled, when adjusted for potency.

CONCLUSIONS

The introduction of FP into New Zealand corresponds with an increase in the total amount of ICS dispensed and an increase in the adjusted daily dose prescribed.

摘要

目的

比较新西兰儿童吸入性糖皮质激素(ICS)的配药剂量和处方剂量。

设计

利用新西兰皇家全科医生学院研究单位数据库和新西兰健康信息系统的药房仓库数据库对处方趋势进行纵向分析。

地点

1993年至2001年的新西兰。

研究对象

0至5岁和6至17岁的儿童。

主要观察指标

丙酸氟替卡松(FP)与倍氯米松(BDP)的效价调整后平均日剂量之比,以及FP、BDP和布地奈德的配药剂量。

结果

0至17岁儿童处方中FP与BDP的效价调整后平均日剂量之比在1.22至1.91之间。随着FP的引入,经效价调整后,新西兰0至5岁儿童ICS的配药总量几乎翻了一番。

结论

FP在新西兰的引入与ICS配药总量的增加以及处方中调整后日剂量的增加相对应。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验